We provided evidence of how VSV-S enhances CD8+ T cell-mediated antitumor immunity and demonstrated that the combination of VSV-S with PD1 blockade offers a synergistic therapeutic strategy for HNSCC. Here, CD8A is linked to head and neck squamous cell carcinoma.